100.30
+1.81(+1.84%)
Currency In USD
| Previous Close | 98.49 |
| Open | 96.55 |
| Day High | 102.2 |
| Day Low | 95.27 |
| 52-Week High | 116 |
| 52-Week Low | 45.91 |
| Volume | 916,051 |
| Average Volume | 618,917 |
| Market Cap | 6.69B |
| PE | -31.74 |
| EPS | -3.16 |
| Moving Average 50 Days | 103 |
| Moving Average 200 Days | 76.15 |
| Change | 1.81 |
If you invested $1000 in Rhythm Pharmaceuticals, Inc. (RYTM) since IPO date, it would be worth $4,082.21 as of November 10, 2025 at a share price of $100.3. Whereas If you bought $1000 worth of Rhythm Pharmaceuticals, Inc. (RYTM) shares 5 years ago, it would be worth $4,191.39 as of November 10, 2025 at a share price of $100.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
GlobeNewswire Inc.
24 minutes ago
– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data from Phase 3 TRANSCEND trial show clinically mean
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
GlobeNewswire Inc.
Nov 07, 2025 12:30 PM GMT
-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
GlobeNewswire Inc.
Nov 05, 2025 9:01 PM GMT
IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHBBOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RY